Provider of clinical research and development services intended to treat systemic and life-threatening fungal infections. The company's services focus on the improvement of Amphotericin B drug, enabling patients to receive a broad-spectrum of antifungal drug that is completely non-toxic in mammalian cells.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
1. Seed Round | 22-Jan-2018 | $30M | 0000 | 0000 | Completed | Startup |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 000 |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Martin Burke Ph.D | Founder |
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Illinois Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |